Table 6.
Results of selected parameters in HIV-infected men after cART in the subgroup with protease inhibitors (PIs) treatment and the subgroup with integrase transfer inhibitors (INSTIs) treatment with statistical analysis.
| Parameters | PIs (N = 25) |
INSTIs (N = 28) |
p * |
|---|---|---|---|
| Me (IQR) | Me (IQR) | ||
| HIV-Infected Men after cART (B) | |||
|
IRS
[ng/mL] |
2.90 (2.30–15.90) | 10.60 (2.90–77.40) | 0.18 |
|
MSTN
[ng/mL] |
160.00 (105.20–917.90) | 484.70 (110.60–3589.00) | 0.20 |
|
PYY
[pg/mL] |
54.50 (32.60–205.50) | 201.20 (30.10–666.60) | 0.08 |
|
GLP-1
[ng/mL] |
159.30 (124.30–709.20) | 661.80 (150.00–3484.00) | 0.09 |
|
DPP-4
[ng/mL] |
70.90 (48.30–541.80) | 395.80 (52.60–1452.00) | 0.14 |
|
FETU-A
[ng/mL] |
224.25 (142.80–1433.00) | 1267.00 (173.50–5173.00) | 0.33 |
|
PTX3
[ng/mL] |
1.95 (1.20–9.80) | 8.10 (1.50–43.70) | 0.31 |
|
SDF-1
[ng/mL] |
1.15 (0.70–5.20) | 5.20 (0.80–41.10) | 0.22 |
|
RANTES
[ng/mL] |
240.40 (155.40–999.10) | 893.90 (169.30–4804.00) | 0.24 |
Abbreviation: cART—combined antiretroviral therapy; B—HIV-infected man after cART; PIs—protease inhibitors treatment; INSTIs—integrase transfer inhibitors; Me—median; IQR—interquartile range; N—number of participants; NS—not statistically significant; IRS—irisin; MSTN—myostatin; PYY—peptide YY; GLP-1—glucagon-like peptide-1; DPP-4—dipeptidyl peptidase IV; FETU-A—fetuin A; PTX 3—pentraxin 3; SDF-1—chemokine stromal cell-derived factor 1; and RANTES—regulated activation normal T cell expressed and secreted. * p—statistical significance by Wilcoxon test.